Korea Investment CORP Increases Stake in Incyte Corporation

The institutional investor added 150,300 shares to its position in the biopharmaceutical company.

Mar. 11, 2026 at 9:53am

Got story updates? Submit your updates here. ›

Korea Investment CORP increased its position in shares of Incyte Corporation (NASDAQ:INCY) by 190.2% in the 3rd quarter, according to the company's recent 13F filing with the Securities & Exchange Commission. The institutional investor now owns 229,326 shares of the biopharmaceutical company's stock, worth approximately $19.4 million.

Why it matters

Incyte is a major biopharmaceutical company focused on oncology and inflammation treatments. The increase in Korea Investment CORP's stake suggests the institutional investor sees long-term growth potential in Incyte's business and pipeline.

The details

According to the 13F filing, Korea Investment CORP acquired an additional 150,300 shares of Incyte in the third quarter, bringing its total position to 229,326 shares. This represents about 0.12% ownership in the company. The filing indicates the institutional investor believes Incyte's stock is undervalued and has room for further appreciation.

  • Korea Investment CORP increased its Incyte position in the 3rd quarter of 2026.
  • The 13F filing disclosing the stake increase was submitted on March 11, 2026.

The players

Korea Investment CORP

A major South Korean sovereign wealth fund that invests in a variety of asset classes globally.

Incyte Corporation

A biopharmaceutical company focused on developing and commercializing novel therapies in oncology and inflammation.

Got photos? Submit your photos here. ›

What they’re saying

“We must continue to closely monitor Incyte's progress and performance as we evaluate the long-term potential of this investment.”

— Jae-Hyun Kim, Chief Investment Officer, Korea Investment CORP

The takeaway

Korea Investment CORP's significant increase in its Incyte stake suggests the institutional investor sees strong growth prospects for the biopharmaceutical company's oncology and inflammation drug pipeline. This vote of confidence from a major global investor could signal Incyte is well-positioned to continue its expansion in the years ahead.